New combo aims to boost CAR-T success in Hard-to-Treat lymphoma
NCT ID NCT07489989
First seen Mar 25, 2026 · Last updated May 20, 2026 · Updated 6 times
Summary
This study tests whether adding two drugs—chidamide and a PD-1 inhibitor—after CAR-T cell therapy can help prevent relapse in people with aggressive B-cell lymphoma that has come back or not responded to treatment. About 30 participants will receive this maintenance therapy to see if it improves how long they stay cancer-free. The goal is to make CAR-T therapy work better and longer for this tough-to-treat cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chinese PLA General Hospital
RECRUITINGBeijing, Beijing Municipality, 100853, China
Conditions
Explore the condition pages connected to this study.